India, Aug. 6 -- Astria Therapeutics (ATXS), Wednesday announced has granted exclusive development and commercialization rights in Japan for its investigational therapy navenibart to Kaken Pharmaceutical.
Navenibart, a long-acting monoclonal antibody in Phase 3 trials, is designed for the preventative treatment of hereditary angioedema.
Under the agreement, Astria will receive an upfront payment of $16 million, with the potential for another $16 million in milestone payments, along with tiered royalties of up to 30 percent and partial cost reimbursement for Phase 3 development.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Kaken will support the ongoing ALPHA-ORBIT Phase 3 trial in Japan, manage re...